# Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

> **NCT06668389** · PHASE4 · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 106 (estimated)

## Conditions studied

- Congenital Heart Disease
- Repaired Tetralogy of Fallot (rTOF)
- Pulmonary Regurgitation
- Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
- Dapagliflozin (Forxiga)

## Interventions

- **DRUG:** SGLT2 inhibitor (Dapagliflozin 10mg)

## Key facts

- **NCT ID:** NCT06668389
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668389, "Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06668389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*